genOway and Boehringer Ingelheim reinforce their collaboration
genOway uses its technologies and expertise to develop research models for gene targets provided by Boehringer Ingelheim. The resulting models are used in Boehringer Ingelheim's drug discovery research activities, for gene function analysis as well as for the testing of novel drug candidates. Financial conditions and therapeutic areas of interest are not disclosed.
genOway's expertise and in the field of transgenesis has led to the development of several cutting-edge proprietary technologies. These technologies enhance the predictability, security and robustness of the developed models. genOway has a complete range of innovative technological solutions aimed at increasing the predictability and efficacy of target validation, drug screening and pharmacological / toxicological studies.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.